iiinova — where your digital self keeps evolving

USC Schaeffer @schaeffer.usc.edu · 26/08/2026

📅Voter turnout in the midterms will be shaped by an often-overlooked factor: friends & family. Join USC Schaeffer researchers and voting rights advocates on Sept. 15 for a conversation on how social circles influence voter intentions. Register here: schaeffer.usc.edu/event/do-you...

020

USC Schaeffer @schaeffer.usc.edu · 24/06/2026

Dementia costs are staggering yet largely hidden. Our new research estimates that dementia will cost the U.S. $818B this year, driven by often-overlooked costs to people with dementia and family & friends providing care. Our research in @alzdemjournals.bsky.social: schaeffer.usc.edu/research/dem...

Text graphic stating "$818B The Cost of Dementia in the U.S. in 2026" with "USC Schaeffer" at the bottom, on a red background.

010

USC Schaeffer @schaeffer.usc.edu · 17/06/2026

Cell and gene therapies are transforming medicine, but significant questions remain about cost, reimbursement & access. Hear USC Schaeffer's Darius Lakdawalla break down these issues in tomorrow's webinar from @mhexecutive.bsky.social. ✒️Registration: globalmeet.webcasts.com/starthere.js...

000

USC Schaeffer @schaeffer.usc.edu · 07/04/2026

The next step in #PBM reform: greater transparency around PBM compensation and enforceable fiduciary responsibility so PBMs must act in clients' best interests, USC Schaeffer's Neeraj Sood writes in Stat. Read here: schaeffer.usc.edu/research/pbm...

010

USC Schaeffer @schaeffer.usc.edu · 01/04/2026

📅How do we rebuild global trust in democracy? Join us 4/22 for a timely conversation on strengthening democratic institutions and civic life with former UK Prime Minister Gordon Brown, chair of USC Schaeffer's new Center for Civic Society. 🔗Event info: schaeffer.usc.edu/event/restor...

000

USC Schaeffer @schaeffer.usc.edu · 19/03/2026

Cell and gene therapies hold tremendous promise for patients, but most lack access. Current efforts to expand access fall short. Our new white paper proposes a phased approach, starting with a private-sector financing model to address systemic barriers. 🔗 schaeffer.usc.edu/research/cel...

000

USC Schaeffer @schaeffer.usc.edu · 10/02/2026

93% of Medicaid managed care prescriptions and 75% of Medicare Part D prescriptions are filled in states where PBM markets are highly concentrated, finds new USC Schaeffer research. schaeffer.usc.edu/research/pbm...

000

USC Schaeffer @schaeffer.usc.edu · 14/01/2026

📽️The search for new #Alzheimers treatments depends on faster, more effective trials. The USC Clinical Trial Recruitment Lab recently brought together leading experts to explore promising recruitment strategies. Watch the full event here: www.youtube.com/watch?v=Qm47...

000

USC Schaeffer @schaeffer.usc.edu · 10/12/2025

📢Making #Alzheimers clinical trials faster, stronger and more representative. Our new Clinical Trial Knowledge Hub shares lessons from the field and key insights on what works. Explore here: schaeffer.usc.edu/clinical-tri...

USC Schaeffer Clinical Trial Knowledge Hub graphic showing connected red hexagons with icons for people, brain, droplet, dollar sign, smartphone, and speech bubble. Gray hexagons form the background. Title at bottom reads 'Clinical Trial Knowledge Hub.'"

000

USC Schaeffer @schaeffer.usc.edu · 25/11/2025

📅 Meeting the urgent need for #Alzheimers treatments requires a stronger, more efficient system for recruiting patients into trials. Join the USC Clinical Trial Recruitment Lab on Dec. 4 to hear from leading experts. Info and registration: schaeffer.usc.edu/event/improv...

A promotional graphic for the event “Improving the U.S. Clinical Trial Recruitment Ecosystem for Alzheimer’s Disease,” hosted by the USC Clinical Trial Recruitment Lab, which consists of USC Schaeffer and the Keck School of Medicine of USC Alzheimer’s Therapeutic Research Institute. The graphic features headshots of eight speakers across two rows: Paul Aisen (ATRI, Keck School of Medicine of USC), Eric Anderson (Synapticure), Niranjan Bose (Gates Ventures), Jeffrey Burns (University of Kansas), Dana Goldman (USC Schaeffer Institute), Mireille Jacobson (USC Schaeffer Institute), Doris Molina-Henry (ATRI, Keck School of Medicine of USC), and Roy Yaari (Eli Lilly and Company). The background is yellow and gold with USC branding elements and a small illustration of cognitive-health icons in the bottom right corner.

000

USC Schaeffer @schaeffer.usc.edu · 07/10/2025

Pfizer's deal with the White House grabbed headlines, but its actual impact is uncertain. USC Schaeffer's Dana Goldman discusses with @nam.edu the challenges of patchwork drug pricing efforts and the need for a more rational pricing system. Read the interview here: nam.edu/news-and-ins...

Quote from Dana Goldman: I don’t think there is enough attention to the fundamental question that should matter for Americans: how should drug prices reflect the values held by Americans? And how can we make reimbursement decisions that get us closer to recognizing that value?

011

USC Schaeffer @schaeffer.usc.edu · 20/08/2025

📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster. Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more ➡️Registration: schaeffer.usc.edu/event/reform...

Reforming the FDA to Meet Today's Innovation Challenges
Friday, Sept. 19, 9-11 am ET
USC Capital Campus
Hosted by USC Schaeffer

041

USC Schaeffer @schaeffer.usc.edu · 21/03/2025

We’re excited to welcome Jonathan Blum, Phyllis Ferrell and Ryan Long to #USCSchaeffer as our newest scholars! Learn more about all our scholars here: schaeffer.usc.edu/people/

000